Matthew A Brown Selected Research

Chondrocalcinosis (Pseudogout)

1/2017	Combined approach for finding susceptibility genes in DISH/chondrocalcinosis families: whole-genome-wide linkage and IBS/IBD studies.
1/2014	Effectiveness and safety of infliximab in two cases of severe chondrocalcinosis: nine years of follow-up.
6/2012	Novel ANKH amino terminus mutation (Pro5Ser) associated with early-onset calcium pyrophosphate disease with associated phosphaturia.
5/2005	Genetic studies of chondrocalcinosis.
4/2005	Association of sporadic chondrocalcinosis with a -4-basepair G-to-A transition in the 5'-untranslated region of ANKH that promotes enhanced expression of ANKH protein and excess generation of extracellular inorganic pyrophosphate.
10/2002	Autosomal dominant familial calcium pyrophosphate dihydrate deposition disease is caused by mutation in the transmembrane protein ANKH.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Matthew A Brown Research Topics

Disease

36	Ankylosing Spondylitis 04/2022 - 10/2004
13	Inflammation (Inflammations) 01/2020 - 01/2005
11	Rheumatoid Arthritis 11/2017 - 09/2002
9	Arthritis (Polyarthritis) 01/2021 - 01/2005
7	Psoriasis (Pustulosis Palmaris et Plantaris) 01/2022 - 11/2010
6	Axial Spondyloarthritis 01/2022 - 08/2012
6	Necrosis 01/2022 - 11/2015
6	Spondylitis 01/2019 - 07/2012
6	Chondrocalcinosis (Pseudogout) 01/2017 - 10/2002
5	Osteoporosis 01/2020 - 03/2005
5	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 01/2019 - 06/2002
5	Neoplasms (Cancer) 11/2018 - 10/2012
4	Non-Radiographic Axial Spondyloarthritis 01/2022 - 06/2013
4	Crohn Disease (Crohn's Disease) 01/2021 - 06/2002
4	Disease Progression 01/2017 - 03/2011
4	Joint Diseases (Joint Disease) 06/2014 - 04/2006
3	Genetic Risk Score 04/2022 - 01/2020
3	Sacroiliitis 01/2022 - 01/2018
3	Hypertension (High Blood Pressure) 01/2022 - 01/2020
3	Type 2 Diabetes Mellitus (MODY) 01/2021 - 02/2011
3	Back Pain (Backache) 01/2021 - 06/2013
3	Ileitis 01/2021 - 07/2012
3	Spondylarthropathies 01/2020 - 04/2015
3	Disease Susceptibility (Diathesis) 01/2019 - 02/2010
3	Genetic Predisposition to Disease (Genetic Predisposition) 08/2016 - 09/2002
3	Multiple Sclerosis 10/2010 - 03/2010
2	Systemic Scleroderma (Systemic Sclerosis) 06/2022 - 01/2021
2	Autoimmune Diseases (Autoimmune Disease) 06/2022 - 01/2019
2	Uveitis 01/2022 - 07/2012
2	Hemorrhage 10/2021 - 01/2021
2	Dysbiosis 01/2021 - 10/2020
2	Adenocarcinoma 01/2021 - 10/2012
2	Hypertrophy 01/2021 - 04/2005
2	Heart Failure 01/2021 - 01/2020
2	Nevus (Nevi) 01/2019 - 11/2018
2	Melanoma (Melanoma, Malignant) 01/2019 - 11/2018
2	Pain (Aches) 01/2018 - 03/2014
2	Immune System Diseases (Immune Disorders) 01/2018 - 01/2016
2	Calcinosis 01/2015 - 01/2012
2	Asthma (Bronchial Asthma) 06/2014 - 09/2011
2	Osteoarthritis 12/2013 - 02/2012
2	Jeune syndrome 11/2013 - 11/2013
2	Ciliopathies 11/2013 - 11/2013
2	Ankylosis 11/2012 - 01/2012
2	Spondylarthritis (Spinal Arthritis) 07/2012 - 06/2002
2	Myositis Ossificans (Fibrodysplasia Ossificans Progressiva) 03/2011 - 05/2006

Drug/Important Bio-Agent (IBA)

14	Proteins (Proteins, Gene)FDA Link 01/2020 - 10/2002
9	HLA-B27 Antigen (HLA B27 Antigen)IBA 04/2022 - 07/2011
8	HLA-B Antigens (HLA-B)IBA 01/2020 - 09/2011
7	Biological ProductsIBA 01/2022 - 02/2014
7	C-Reactive ProteinIBA 01/2021 - 01/2009
7	HLA-DRB1 Chains (HLA DRB1)IBA 01/2019 - 01/2003
6	HLA Antigens (Human Leukocyte Antigens)IBA 01/2022 - 10/2010
6	Interleukin-23 (Interleukin 23)IBA 01/2022 - 04/2009
6	Biomarkers (Surrogate Marker)IBA 01/2020 - 02/2012
6	Ethylnitrosourea (N-Ethyl-N-nitrosourea)IBA 01/2019 - 01/2012
5	CytokinesIBA 01/2017 - 01/2005
5	diphosphoric acid (pyrophosphoric acid)IBA 01/2012 - 04/2005
4	DNA (Deoxyribonucleic Acid)IBA 04/2022 - 08/2007
4	Tumor Necrosis Factor InhibitorsIBA 01/2022 - 01/2014
4	InterleukinsIBA 01/2022 - 02/2010
4	AntigensIBA 01/2020 - 01/2007
4	AminopeptidasesIBA 01/2018 - 07/2011
4	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2018 - 01/2003
4	Amino Acids FDA Link 10/2017 - 12/2014
4	Proteoglycans (Proteoglycan)IBA 01/2017 - 11/2012
4	Peptides (Polypeptides)IBA 01/2015 - 07/2011
3	Interleukin-17 (Interleukin 17)IBA 01/2022 - 01/2013
3	AutoantibodiesIBA 01/2021 - 01/2009
3	curdlanIBA 01/2021 - 07/2012
3	Pharmaceutical PreparationsIBA 11/2020 - 02/2014
3	HLA-C Antigens (HLA-C)IBA 01/2019 - 11/2010
3	Calcium PyrophosphateIBA 01/2017 - 10/2002
3	RNA (Ribonucleic Acid)IBA 12/2013 - 03/2011
3	Interleukin-1 (Interleukin 1)IBA 01/2013 - 10/2004
3	EnzymesIBA 01/2013 - 05/2011
2	Methotrexate (Mexate)FDA LinkGeneric 01/2022 - 09/2021
2	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 11/2020 - 06/2013
2	HLA-A Antigens (HLA-A)IBA 10/2020 - 01/2019
2	EpitopesIBA 01/2020 - 04/2014
2	Uric Acid (Urate)IBA 01/2020 - 01/2011
2	Untranslated RNA (Noncoding RNA)IBA 01/2020 - 06/2016
2	LigandsIBA 01/2020 - 01/2009
2	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2020 - 07/2012
2	Fibrillin-1IBA 01/2020 - 01/2016
2	micaIBA 01/2020 - 11/2018
2	HLA-DPB1 antigen (HLA DPB1)IBA 01/2019 - 10/2010
2	Leukocyte L1 Antigen Complex (Calgranulin)IBA 01/2018 - 01/2009
2	Aligeron (AS 2)IBA 01/2018 - 04/2005
2	Serine (L-Serine)FDA Link 10/2017 - 03/2011
2	Interleukin-6 (Interleukin 6)IBA 11/2015 - 01/2013
2	Phosphates (Orthophosphate)IBA 01/2015 - 04/2012
2	P-2 (P 2)IBA 06/2014 - 01/2013
2	Initiator Codon (Start Codon)IBA 03/2014 - 04/2005
2	Adrenal Cortex Hormones (Corticosteroids)IBA 03/2014 - 01/2005
2	OsteocalcinIBA 03/2014 - 11/2012

Therapy/Procedure

13	Therapeutics 01/2021 - 01/2005
3	Transjugular Intrahepatic Portasystemic Shunt 10/2021 - 02/2020
3	Surgical Portasystemic Shunt (Portosystemic Shunt) 10/2021 - 02/2020
2	Endurance Training 01/2022 - 01/2021